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 3 
ABSTRACT 50 
Scedosporium apiospermum is a medically important fungal pathogen that causes a wide 51 
range of infections in humans.  There are relatively few antifungal agents that are active 52 
against Scedosporium spp.  Little is known about the pharmacodynamics of voriconazole 53 
against Scedosporium.  Both static and dynamic in vitro models of invasive scedosporiosis 54 
were developed. Monoclonal antibodies that target a soluble cell wall antigen secreted by 55 
Scedosporium apiospermum were used to describe the pharmacodynamics of voriconazole.  56 
Mathematical pharmacokinetic-pharmacodynamic models were fitted to the data to estimate 57 
the drug exposure required to suppress the release of fungal antigen.  The experimental 58 
results were bridged to humans using Monte Carlo simulation.  All 3 strains of S. 59 
apiospermum tested invaded through the cellular bilayer of the in vitro models and liberated 60 
antigen.  There was a concentration-dependent decline in antigen with near maximal 61 
antifungal activity in all 3 strains with 10 mg/L.  Similarly, there was a drug exposure 62 
dependent decline in circulating antigen in the dynamic model and complete suppression of 63 
antigen with an AUC of approximately 80 mg.h/L.  A regression of the AUC:MIC versus area 64 
under the antigen time curve showed that near maximal effect was obtained with AUC:MIC 65 
of approximately 100.  Monte Carlo simulation suggested that only isolates with an MIC of 66 
0.5 mg/L enable pharmacodynamic targets to be acheived with a standard regimen of 67 
voriconazole.  Isolates with higher MICs may need higher drug exposure targets than are 68 
currently recommended for other fungi. 69 
 70 
 71 
 72 
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 75 
INTRODUCTION 76 
Scedosporium spp. are environmentally ubiquitous hyaline moulds (1).  Scedosporium 77 
apiospermum is a medically important member of the Scedosporium genus that also 78 
comprises Scedosporium boydii, Scedosporium angustum, Scedosporium minutisporum, 79 
Scedosporium dehoogii, and Scedosporium aurantiacum (2, 3). Infections caused by these 80 
pathogens occur in a range of contexts that include near-drowning, solid organ 81 
transplantation, chronic lung disease (e.g. cystic fibrosis) and otherwise seemingly 82 
immunocompetent hosts (1).  Scedosporium spp. cause diseases that are as disparate as 83 
mycetoma, airway colonisation in cystic fibrosis, pneumonia, skin and soft tissue infection 84 
and disseminated infection (4).  The fungus is neurotropic and central nervous system 85 
infection has been demonstrated in experimental models of infection, and is apparent from a 86 
multitude of case studies and series (5–9).  87 
Voriconazole is considered a first-line agent for the treatment of invasive infections 88 
caused by Scedosporium apiospermum (10).  The overall treatment response for infections 89 
caused by Scedosporium spp. is approximately 43% (11).  This disappointingly low figure 90 
raises several issues.  The first is uncertainty surrounding the optimal use of voriconazole for 91 
Scedosporium spp.  There is no specific information for this indication that informs the 92 
optimal regimen, targets for therapeutic drug monitoring or in vitro susceptibility 93 
breakpoints.  The second is the paucity of antifungal agents that are effective for 94 
Scedosporium spp.  The advent of newer triazoles such as posaconazole and isavuconazole do 95 
not appear to offer a significant therapeutic advance over voriconazole for the treatment of 96 
these fungi.  There are no experimental pharmacodynamic models of invasive scedosporiosis 97 
that enable current antifungal agents to be optimised or newer antifungal agents to be 98 
developed.  99 
 Here, we adapt an existing in vitro cell culture model of the human alveolus that has 100 
been used for Aspergillus fumigatus (12) and Aspergillus flavus (13) infections to develop a 101 
new model of invasive pulmonary scedosporiosis.  The key step in the development of the 102 
model described in this study was the use of a double- sandwich monoclonal antibody (mAb)-103 
based ELISA for the quantification of a soluble cell wall antigen shown previously to be an 104 
accurate biomarker for tracking species in the Scedosporium apiospermum complex (14).  The 105 
antigen provided a continuous assessment of the interaction of voriconazole with its fungal 106 
target potentially in the same way as galactomannan has been used for Aspergillus spp.  A 107 
deep understanding of the pharmacodynamics of voriconazole against Scedosporium enables 108 
the design of optimised treatment regimens and is fundamental to establishing in vitro 109 
susceptibility breakpoints.  110 
  111 
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 5 
RESULTS 112 
Provenance, Identification and In Vitro Susceptibility Testing  113 
Two strains were obtained from the Spanish Mycology Reference Laboratory and a 114 
further strain from the Regional Mycology Laboratory, University Hospital, South Manchester 115 
(Table 1).  No details were available as to the relevant clinical details.  The three isolates used 116 
in this study were identified as Scedosporium apiospermum based on sequencing of the ITS 117 
and ß-tubulin genes and searching within the FUNCBS.txt database.  The MICs using Clinical 118 
Laboratory Sciences Institute (CLSI) methodology are shown in Table 1.  Strains with 119 
voriconazole MICs of 0.5-1 mg/L were used for experiments so as to study isolates largely 120 
representative of a susceptible population according to MIC90 values (21). 121 
 122 
Static models of the human alveolus 123 
A previously described cellular bilayer model of the human alveolus (15) was used to 124 
study the pharmacodynamics of voriconazole against Scedosporium apiospermum.  The  125 
bilayer is comprised of a layer of human pulmonary arterial endothelial cells and human 126 
alveolar epithelial cells.  The bilayer delineates an airspace (alveolar compartment) and blood 127 
space (endothelial compartment).  Previous studies of Aspergillus spp. have used 128 
galactomannan as a biomarker to assess fungal invasion through the cellular bilayer and 129 
quantify the response to antifungal therapy (12, 15).  In the current study, a novel cell wall 130 
antigen liberated by Scedosporium spp. during growth was used (see below) for this purpose. 131 
Following inoculation of macroconidia into the alveolar compartment and subsequent 132 
germination, there was progressive liberation of antigen in the endothelial compartment 133 
(Figure 1).  Antigen appeared in the endothelial compartment approximately 24 hours after 134 
inoculation and plateaued thereafter.   135 
The exposure-response relationships for voriconazole in the static model of invasive 136 
pulmonary scedosporiosis are shown in Figure 2.  In these experiments, voriconazole was 137 
administered to the endothelial compartment 6-hours post inoculation from where it 138 
distributed into the cellular bilayer and into the alveolar compartment.  There was more 139 
pharmacodynamic variability in the alveolar compartment than the endothelial compartment 140 
as evidenced by the larger standard deviation of the experimental replicates.  Some of the 141 
exposure response relationships in the alveolar compartment were right-shifted with respect 142 
to those in the endothelial compartment.  This was apparent from the data and the estimates 143 
of EC50 from the inhibitory sigmoid Emax relationship.  Maximal antifungal activity, as 144 
estimated using the release of antigen, was achieved in both the alveolar and endothelial 145 
compartments of all strains with voriconazole concentrations of approximately 10 mg/L 146 
(Figure 2).  Nevertheless, there was significant strain-to-strain variability in the 147 
pharmacodynamics of voriconazole. 148 
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 149 
Dynamic models of the human alveolus 150 
A dynamic model of invasive pulmonary scedosporiosis was developed to enable the 151 
pharmacodynamics in response to human-like pharmacokinetic profiles of voriconazole to be 152 
examined.  Purpose-built bioreactors have previously been described as has the circuitry that 153 
enables the simulation of human-like pharmacokinetics (12).   Samples to estimate the 154 
pharmacokinetics and pharmacodynamics of voriconazole were taken from medium passing 155 
through the endothelial compartment of the dynamic in vitro model.   156 
In untreated circuits, there was a progressive increase in antigen concentrations 157 
through the experimental period.  A human-like PK profile of voriconazole was simulated in 158 
the dynamic model with average AUC72-96 that ranged from 7.84-80.68 mg.h/L.  These drug 159 
exposures were based on preliminary experiments, prior knowledge of the 160 
pharmacodynamics of voriconazole against filamentous fungi, and were also designed to 161 
encompass the entire exposure-response relationship for Scedosporium apiospermum.   162 
There was a drug-exposure-dependent decline in antigen concentrations.  As the AUC 163 
increased, there was progressively larger suppression of circulating antigen concentrations 164 
(Figure 3).  An AUC0-24 of approximately 80 mg.h/L resulted in complete suppression of 165 
antigen release from all three strains (Figure 3).  There was no evidence of a paradoxical 166 
effect with even higher drug exposures (data not shown). 167 
 168 
Mathematical modelling 169 
 A linked pharmacokinetic-pharmacodynamic mathematical model was fitted to the 170 
entire experimental dataset using the population pharmacokinetic program Pmetrics (16).  171 
The mathematical model fitted the PK-PD data well (Figure 4).  The median parameter values 172 
fitted the data better than the means and are shown in Table 2.  The Bayesian estimates for 173 
each arm (circuit) were used to calculate the area under the voriconazole concentration-time 174 
curve for each regimen from 72 to 96 hours post initiation of voriconazole using the 175 
trapezoidal rule.  Similarly, the area under the antigen-time curve was estimated from the 176 
time of treatment initiation (i.e.  time =0) to 96 hours post initiation of voriconazole using the 177 
Bayesian posterior estimates of each circuit and the trapezoidal rule.   178 
  179 
Pharmacodynamics of voriconazole  180 
The estimates for both the voriconazole AUC72-96 and AUC72-96:MIC versus the area 181 
under the antigen-time curve were used to establish pharmacodynamic relationships for 182 
voriconazole against Scedosporium apiospermum.  Inhibitory sigmoid Emax models fitted to 183 
the data suggested that an AUC and AUC:MIC of 16.69 mg*h/L and 22.88, respectively was 184 
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 7 
associated with half-maximal effect (Figure 5).  The shape and coefficient of determination 185 
for the two regressions were similar, but the AUC:MIC versus effect relationship was slightly 186 
right-shifted. 187 
 188 
Bridging to Humans 189 
A standard licenced regimen was used for the simulation (i.e. 6 mg/kg i.v. q12h for 190 
two dosages followed by 4 mg/kg q12h i.v.).  Voriconazole was infused over 1 hour.  The 191 
AUC0-24 at the end of 5 days of therapy was calculated using integration.  Each simulated 192 
patient’s AUC was divided by the MIC to calculate AUC:MIC for each MIC value. The 193 
proportion of simulated patients achieving (or exceeding) the pharmacodynamic target at 194 
each MIC was determined.  The expectation of overall target attainment across the 195 
population was 34%. 196 
 197 
  198 
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 8 
DISCUSSION 199 
 There is only limited information on the MIC distribution of Scedosporium 200 
apiospermum.  MICs estimated using Clinical Laboratory Sciences Institute (CLSI) M-38A 201 
methodology suggests that the MIC50 and MIC90 is 1 and 2 mg/L, respectively (17).  Inspection 202 
of the MIC distribution of strains described in this study suggests that the epidemiological 203 
cut-off value for voriconazole is 4 mg/L.  Using an AUC:MIC pharmacodynamic target of 100 204 
(that is associated with complete suppression of circulating antigen in the in vitro cell culture 205 
model) the currently licenced regimen of voriconazole (i.e. 6 mg/kg q12h for two dosages 206 
followed by 4 mg/kg q12h) has an overall probability of target attainment of 34% (i.e. 34% of 207 
simulated patients are predicted to have complete suppression of the circulating antigen 208 
when assessed against a distribution of MICs).  These simulations provide experimental 209 
support a breakpoint of 0.5 mg/L, which is less than the epidemiological cutoff value of 4 210 
mg/L.  These conclusions are based upon an AUC:MIC target of 100, which needs further 211 
validation using further experimental and clinical data.  212 
Immunosuppressed murine models of disseminated infection of Scedosporium spp. 213 
have been developed and used to assess pathogenesis and efficacy of various antifungal 214 
agents.  The primary model readouts include survival, and the fungal burden in kidneys, 215 
spleen, brain, liver and lungs.  Infection is initiated by i.v. injection of conidia, rather than the 216 
usual clinically relevant route of infection (i.e. inhalation of conidia) (5, 18, 19).  Disseminated 217 
models of fungal infection may not be ideal to establish pharmacodynamic relationships 218 
because they are not faithful mimics of human pathogenesis and disease.  The model 219 
endpoints are also a potential issue.  For example, survival in mice is  confounded by mixing 220 
efficacy and drug-related toxicity.  There are also well-established problems in performing 221 
quantitative counts from tissue homogenates to assess the fungal burden of moulds (see, for 222 
example, (20)).  These limitations are further compounded by the complex pharmacology of 223 
many antifungal agents.  For example, voriconazole is notoriously difficult to study in mice 224 
because of auto-induction of clearance, and a pharmacokinetic profile that is significantly 225 
different from humans (21).  Hence, alternative model systems of invasive scedosporiosis are 226 
required to assess the pharmacodynamics of new and existing antifungal agents.   227 
We have previously developed static and dynamic models of the human alveolus to 228 
describe the pharmacodynamics of voriconazole against Aspergillus spp.  Outputs from these 229 
models have aligned well with the available data from laboratory animal models and clinical 230 
datasets (12, 13, 15).  This has motivated the development of newer models for other 231 
medically important fungi.  The use of galactomannan as a biomarker circumvents the 232 
problems in directly quantifying the burden of Aspergillus in tissue beds, and enables direct in 233 
vivo-to-clinical correlations.  Galactomannan cannot however be used for fungi other than 234 
Aspergillus spp. For the Scedosporium studies described here, we used previously 235 
characterised monoclonal antibodies (HG12 and GA3), raised against a cell wall antigen 236 
present in species within the Scedosporium apiospermum complex, to determine S. 237 
apiospermum growth.  The absolute identity of the antigen bound by the mAbs has yet to be 238 
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 9 
determined, but they bind to a carbohydrate epitope on a major 120 kDa glycoprotein 239 
secreted during active growth of Scedosporium spp. (14).  Upon germination of conidia, the 240 
antigen ceases to be expressed on the spore surface and is then produced extracellularly by 241 
developing hyphae (14). The antigen is therefore a potentially useful biomarker for 242 
determining active growth of Scedosporium spp., and for tracking response to antifungal 243 
drugs. 244 
The often-suboptimal clinical outcomes of patients infected with Scedosporium 245 
apiospermum complex provides the impetus to develop new antifungal agents.  The 246 
availability of a range of pharmacodynamic models enables the acquisition of the 247 
underpinning evidence for patients to be enrolled in clinical trials.  While there is a general 248 
paucity of compounds in development pipelines, several new compounds demonstrate in 249 
vitro activity against Scedosporium.  These compounds include F901318 (F2G, Eccles, UK) and 250 
APX001 (Amplyx, San Diego, USA).  These compounds could be further assessed in this 251 
model. 252 
There are several limitations of this study.  Firstly, this is a cell culture model that is 253 
representative of relatively early invasive pulmonary disease.  The pharmacodynamics of 254 
voriconazole may change in later phases of established disease where there is significant 255 
tissue necrosis.  Furthermore, the pharmacodynamic relationships specifically pertain to 256 
invasive pulmonary infection and may not necessarily represent other forms of infection and 257 
disease caused by Scedosporium spp., such as those that involve the central nervous system.  258 
The in vitro model does not contain immunological effectors and does not enable their 259 
adjunctive antifungal effect to be estimated.  This may lead to an overestimate of the 260 
pharmacodynamic target for immunocompetent patient populations.   A novel antigen was 261 
used as a biomarker to assess the pharmacodynamics of voriconazole in this experimental 262 
model.  The clinical relevance of this antigen remains to be determined.  This will require a 263 
combination of experimental and clinical research in the same manner as occurred for 264 
galactomannan. 265 
 Despite potential limitations, this in vitro model provides new insights into the 266 
pharmacodynamics of voriconazole against a less common, but nevertheless medically 267 
important fungal pathogen.  The development of new agents and therapeutic approaches will 268 
require an array of experimental models that allow their pharmacodynamics to be elucidated 269 
and optimised.  The approach of using novel soluble cell wall antigens as biomarkers with 270 
prognostic value provides a way in which the pharmacodynamics of relatively uncommon 271 
pathogens and antifungal compounds with challenging pharmacological properties can be 272 
elucidated. 273 
 274 
  275 
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 276 
METHODS 277 
Identification of Isolates to Species Level 278 
Isolates of Scedosporium apiospermum were obtained from the Regional Mycology 279 
Reference Laboratory, University Hospital of South Manchester and the Mycology Reference 280 
Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain. 281 
Isolates were stored at -80⁰C. 282 
Scedosporium apiospermum was definitively identified via sequencing of the internal 283 
transcribed spacer (ITS) and β-tubulin regions. Extraction of fungal DNA was performed as 284 
follows.  Approximately 20-40 acid-washed glass beads were suspended in 0.5 mL of sterile 285 
distilled water. The strains were grown on oatmeal agar for five days prior to 286 
experimentation.  Mycelia and conidia were harvested by gently abrading the fungus with a 287 
sterile needle before adding to the beads and water. Samples were homogenised using a 288 
FastPrep-24 homogeniser. Filters (2 mm diameter) were cut from Whatman Flinders 289 
Technology Associates classic indicator cards (Whatman International, Kent, United Kingdom) 290 
and inoculated with 2 µL of homogenate. Filters were dried for 10 minutes before being 291 
washed twice with 100 µL sterile distilled water.   292 
For the amplification of DNA, 700 µL of polymerase chain reaction (PCR) reaction mix 293 
was prepared. This consisted of 70 µL buffer (QIAGEN, UK), 7 µL dNTPs (2.5mM), 70 µL 294 
forward primer, 70 µL reverse primers, 420 µL PCR grade H2O, 3.5 µL HotstarTaq (QIAGEN, 295 
UK). The PCR reaction mixture was vortexed for 1 min. A total of 100 µL of PCR reaction 296 
mixture was added to each PCR tube containing the inoculated filter. The PCR reaction 297 
conditions were as follows: 15mins 94⁰C for one cycle, 40 cycles of 30 sec at 94⁰C, 30 sec 298 
50⁰C, 90 sec 72⁰C, one cycle of 7 mins at 72⁰C, 4⁰C for remainder. After the PCR cycle was 299 
completed, 8 µL was transferred to a new PCR tube and 5 µL of the appropriate forward 300 
primer was added for sequencing of the ITS and β-tubulin regions.  301 
Sequencing of the amplicons was performed by Beckman- Coulter Genomics Inc.  302 
Sequences were analysed for identification via the FUNCBS.txt database 303 
(http://www.cbs.knaw.nl/Collections/BioloMICSSequences.aspx). 304 
 305 
Preparation of Inoculum for Experimental Pharmacology 306 
Ten days prior to experimentation, isolates were sub-cultured to oatmeal agar 307 
(Sigma-Aldrich, Poole, UK) and incubated in air at 30⁰C. Conidial suspensions were prepared 308 
by flooding a flask with 20 mL of PBS and simultaneously abrading the surface of the colonies 309 
with a sterile cotton swab. The resulting suspension was filtered through sterile gauze before 310 
being centrifuged for 10 minutes at 2500 rpm and re-suspending the pellet in 10mL PBS. The 311 
washing step was performed twice. For the preparation of the final inoculum, basal cell 312 
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 11 
culture medium,EBM-2, (Promocell, Heidelberg, Germany) was used as the diluent. A conidial 313 
suspension of 1 x 106 CFU/mL was prepared using a haemocytometer and confirmed by 314 
quantitative cultures by plating to Sabouraud agar supplemented with chloramphenicol 315 
(Oxoid Ltd, Basingstoke, UK). 316 
 317 
In vitro Susceptibility Testing 318 
Minimum inhibitory concentrations (MIC) of voriconazole against S. apiospermum 319 
isolates were determined in five independently conducted experiments using Clinical 320 
Laboratory Sciences Institute (CLSI) methodology.  321 
 322 
Cell Culture Models of Invasive Scedosporiosis 323 
Novel cell culture models of invasive pulmonary scedosporiosis were developed to 324 
investigate the pharmacodynamics of voriconazole. These were based on similar models 325 
developed for Aspergillus fumigatus and Aspergillus flavus (12, 13, 15).  Both static and 326 
dynamic models of invasive disease were developed. In the former, drug concentrations were 327 
fixed, as occurs in in vitro susceptibility testing. In the latter, peristaltic pumps were used to 328 
simulate human pharmacokinetics to ensure a more clinically relevant and tractable estimate 329 
of drug exposure. 330 
Both model systems required the construction of a cellular bilayer consisting of 331 
human pulmonary arterial endothelial cells (HPAECs) (Promocell, Heidelberg, Germany) and 332 
human alveolar epithelial cells (A549s; LGC Standards, Middlesex, UK). Cells were seeded on 333 
opposing surfaces of polyester membrane cell culture inserts, as previously described (15). 334 
 335 
Growth of A549 and HPAECs cells 336 
A549 cells were cultured using endothelial basal medium-2 (EBM-2; Invitrogen, 337 
Paisley, UK) medium containing 10% foetal bovine serum (FBS). HPAECs were cultured using 338 
endothelial growth medium (EGM-2) according to the manufacturer’s instructions 339 
(Promocell, Heidelberg, Germany), which consists of EBM-2 supplemented with 2% FBS 340 
(Invitrogen, Paisley, UK), ascorbic acid, heparin, hydrocortisone, human endothelial growth 341 
factor, vascular endothelial growth factor 165, human fibroblast factor B and R-3-insulinlike 342 
growth factor 1.   343 
Once 70-80% confluence was achieved, cells were washed using Hanks Balanced Salt 344 
Solution (HBSS) (Sigma-Aldrich, Poole, UK) and harvested with 6 mL of a 0.25% trypsin–345 
ethylenediaminetetraacetic (EDTA) solution (Sigma-Aldrich, Poole, UK). Cells were then 346 
centrifuged for 5 min. at 2,000 rpm and re-suspended in the appropriate medium to achieve 347 
final density of 5.5 x 105/mL and 1 x 106/mL for A549s and HPAECs, respectively. 348 
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 349 
Construction of the Static Model of Invasive Pulmonary Scedosporiosis 350 
12 mm cell culture inserts with a 3.0 μm pore polyester membrane for 24-well tissue 351 
culture plates (Appleton Woods, Birmingham, UK) were inverted. For the construction of the 352 
endothelial cell layer 100 µL of HPEAC cell suspension was pipetted onto the underside of the 353 
membrane. Inserts were then incubated (37⁰C, 5% CO2) for 2 hours to enable cellular 354 
adhesion to the membrane. Inserts were then transferred to 24-well plates containing 0.6 mL 355 
of EGM-2 medium. One-hundred µL of EBM-2 containing 10% FBS was then added to the 356 
alveolar compartment.  The cell culture plates were then incubated at 37⁰C in 5% CO2 for 24 357 
hours.   358 
After 24 hours, medium from the alveolar compartments was removed and inserts 359 
were transferred to new plates containing the relevant amounts of fresh EGM-2 medium.  360 
One-hundred µL of the A549 suspension was added to the alveolar compartment.  After 2 361 
hours, medium from the alveolar compartment was removed to create an air-liquid interface.  362 
The EGM-2 medium in the bottom compartment was replaced every 48 hours and medium 363 
that had accumulated in the alveolar compartments was removed and discarded. The 364 
bilayers were ready for experimentation after 5 days. 365 
 366 
Construction of the Dynamic Model of Invasive Pulmonary Scedosporiosis 367 
The same process was used for the dynamic models except larger 12-well cell culture 368 
plate inserts were used (Greiner Bio-One, Stonehouse, UK). Larger volumes were required 369 
because of the larger surface areas, hence, 400 µL of the HPAEC suspension, and 400 µL of the 370 
A549 suspension was used to seed the membrane. Inserts were immersed in 1.5 mL of EGM-2 371 
medium in 12-well tissue culture plates. The protocols for establishing the bilayer were the 372 
same as for the static model. 373 
 374 
Pharmacodynamic Experiments Using the Static in Vitro Model of the Human Alveolus 375 
Cell culture inserts were transferred to a 24 well plate containing 0.6 mL of EBM-2 376 
medium supplemented with 2% FBS.  A conidial suspension of 1 x 106 of Scedosporium 377 
apiospermum was prepared and warmed to 37⁰C for 20 minutes. One-hundred µL of the 378 
conidial suspension was inoculated into the alveolar compartment of each cell culture insert 379 
and incubated at 37⁰C in 5% CO2 for 12 hours. The remaining (spent) inoculum was then 380 
removed and discarded to enable an air-liquid interface to re-establish. 381 
Pure voriconazole was dissolved in DMSO (Sigma- Aldrich, Poole) to produce a stock 382 
solution of 3 mg/ml. The desired final concentration of voriconazole for each insert was 383 
achieved by serial dilution of the stock in EBM-2 medium that was supplemented with 2% 384 
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FBS. Medium containing different concentrations of voriconazole was placed in each well 12 385 
hours post inoculation in order to replicate an early invasive infection. Plates were then 386 
incubated at 37°C, 5% CO2 for 48 hrs.  Samples from the endothelial and alveolar 387 
compartments were obtained and stored at −80⁰C for measurement of drug concentrations 388 
and detection of the cell wall antigen. 389 
 390 
Construction of dynamic model 391 
Cell culture inserts were housed in custom-designed stainless steel bioreactors. 392 
Bioreactors were specifically engineered to house individual cell culture inserts and allowing 393 
media to flow past the endothelial layer. All components were autoclaved and circuits were 394 
assembled in a class II safety cabinet. 395 
Each bioreactor was connected to a circuit using Marprene® thermoplastic 396 
elastometer tubing (Watson Marlow, Cornwall, UK). All connections were made using 397 
polypropylene barbed luer adapters (Cole Palmer, London UK; West Group, Hants, UK). A 398 
central reservoir containing 200 mL of warmed media was connected to the circuit using 1.5-399 
mm bore polytetrafluoroethylene (PTFE) semi-rigid tubing (Diba Labware, Kinesis Ltd., 400 
Cambridge, UK) fitted into Omni-Fit Q-series bottle caps (Diba Labware, Kinesis Ltd., 401 
Cambridge, UK). The central reservoir contained a magnetic stirring bar to ensure continuous 402 
mixing of drug. Duran bottles containing fresh medium and empty bottles for the removal of 403 
waste were connected to the central reservoir using Silastic®, 1.6 mm bore tubing (Dow 404 
Corning) to enable the generation of first-order decay in voriconazole concentrations. Two 405 
205-U multichannel cassette peristaltic pumps fitted with 1.52 mm bore Marprene manifold 406 
tubing (Watson Marlow, Cornwall, UK) were used to circulate medium through the circuit 407 
and bioreactor. 408 
Once assembled, circuits were transferred to a 37⁰C incubator for the remainder of 409 
the experiment. Dulbecco’s modified Eagle medium (DMEM) containing 4500 mg/L D-410 
Glucose, L-Glutamine and HEPES buffer (Invitrogen, Paisley, UK) was supplemented with 2% 411 
FBS and a penicillin- streptomycin solution (Sigma-Aldrich, Poole) to give a final concentration 412 
of 100 U/mL penicillin and 0.1 mg/mL streptomycin.  413 
 414 
Pharmacokinetic and Pharmacodynamic Experiments Using the Dynamic in Vitro Model of the 415 
Human Alveolus 416 
Pure voriconazole powder was dissolved in DMSO. Drug was administered directly 417 
into the central compartment as a bolus. Dosages were selected from previously published 418 
data demonstrating the achievement of voriconazole exposures that ranged from sub-419 
optimal to successful in treating organisms of similar susceptibilities in this model (13). 420 
Amounts of 0 mg, 0.1 mg, 0.2 mg, 1 mg and 3 mg were administered every 12 hours to the 421 
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central compartment to achieve initial concentrations of 0, 0.5, 1.5, 5 and 15 mg/L 422 
respectively. The pump connecting the Duran containing fresh medium and the waste was 423 
run to achieve a flow of 10 mL/hour. This was previously demonstrated to generate human-424 
like concentration- time profiles for voriconazole (13).  Voriconazole therapy commenced 12 425 
hours post inoculation (as was the case with the static model described above). 426 
LC/MS/MS 427 
Voriconazole concentrations were measured using a validated ultrahigh-performance 428 
liquid chromatography tandem mass spectrometry method comprising of  a Agilent 6420 429 
Triple Quad Mass spectrometer and a Agilent 1290 infinity LC system (Agilent Technologies 430 
UK Ltd, Cheshire, UK).  Voriconazole was extracted by protein precipitation; 300 µl of 431 
acetonitrile containing the internal standard (IS) Phenacetin 0.1 mg/L (Sigma Aldrich, Dorset, 432 
UK) was added to 100 µl of matrix. The samples were then vortexed for 5 seconds and 433 
centrifuged at 13000 g for 3 minutes. Two hundred µl of the supernatant was removed and 434 
placed in 96 well plate, 3 µl were injected on an Agilent a Zorbax Eclipse Plus C18 (2.1 by 50 435 
mm, 1.8-m particle size) (Agilent Technologies UK Ltd, Cheshire, UK).  436 
Chromatographic separation was achieved using a gradient with the starting 437 
conditions of 70:30 (0.1% formic acid in water as mobile phase A and 0.1% formic acid in 438 
acetonitrile as mobile phase B).  Starting conditions were held for 0.2 minutes, then mobile 439 
phase B was increased to 100% over 1.5 minutes. This was held at 100% mobile phase B for 440 
0.5 minutes, and then reduced to starting conditions for 1 minute of equilibration.  The mass 441 
spectrometer was operated in multiple reaction monitoring (MRM) scan mode in positive 442 
polarity. The precursor ion for voriconazole was 350.0m/z, and it was 180.1 m/z for the IS. 443 
The product ion for voriconazole was 281.1 m/z and it was 110.0 m/z for the IS. The source 444 
parameters were set as 4000 V for capillary voltage, 350°C for gas temperature, and 60 lb/in2 445 
for the nebulizer gas. The standard curve for voriconazole encompassed the concentration 446 
range of 0.025-20.0 mg/L and was constructed using blank matrix. The data were acquired 447 
and processed using the Mass Hunter Quantitation B.6.0 software package.  For voriconazole 448 
in media the limit of detection was 0.0025 mg/L and the limit of quantitation was 0.0025 449 
mg/L. The CV% was 8.9% over the concentration range 0.0025-20.0 mg/L and the intra and 450 
inter-day variation was < 7.2%.  451 
 452 
Enzyme linked immunosorbent assay 453 
Elucidation of the pharmacodynamics of voriconazole against S. apiospermum was 454 
enabled by measuring a soluble cell wall antigen released during active growth of the 455 
pathogen using a double-antibody-sandwich (DAS)-ELISA.  The HG12 and GA3 monoclonal 456 
antibodies used in the DAS-ELISA are specific to Scedosporium spp., and bind to an 457 
extracellular 120-kDa antigen secreted by hyphae following spore germination (14). Fifty µL 458 
volumes of mAb HG12 (IgG1) tissue culture supernatant (TCS) were used to coat the wells of 459 
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Maxisorp microtiter plates (Fisher Scientific, Loughborough, UK).  The plates were incubated 460 
for 16 hours at 4oC before washing four times with PBS containing 0.05% (v/v) Tween 20 461 
(PBST).  The plates were then washed once with PBS and once with distilled water before 462 
being placed in a drying cabinet at 23oC for 1 hour. Plates were stored at 4oC in sealed plastic 463 
bags until used. 464 
Working volumes were 50 µL; all incubation steps were conducted in sealed plastic 465 
bags at 23oC, and wells were washed three times with PBST (5 minutes each time) between 466 
incubations. Wells containing immobilised HG12 were blocked for 10 minutes with 100µL of 467 
PBS containing 1% (w/v) of bovine serum albumin (BSA) to prevent non-specific protein 468 
binding. Blocked wells were then incubated with experimental solutions for 2 hours to allow 469 
antigen capture by mAb HG12. Unbound antigen was removed by washing with PSBT and the 470 
wells then incubated with mAb GA3 (IgM) TCS for 1 hour. Washed wells were then incubated 471 
for 1 hour with goat anti-mouse IgM (µ-chain specific) biotin conjugate (Sigma Aldrich, Poole, 472 
UK) diluted 1:1000 in PBST containing 0.5% (w/v) BSA. After removal of unbound biotin 473 
conjugate by washing with PBST, wells were incubated for a further hour with Extravidin-474 
peroxidase (Sigma-Aldrich, Poole, UK) diluted 1:1000 in PBST containing 0.5% (w/v) BSA. After 475 
washing with PBST and a single rinse with PBS, bound antibody-antigen complexes were 476 
visualized by incubating wells in tetramethyl benzidine (TMB) substrate solution (Sigma- 477 
Aldrich, Poole, UK) for 30 minutes.  Reactions were stopped by the addition of 3M H2SO4 and 478 
absorbance values determined at 450 nm. 479 
Mathematical Modelling 480 
A population methodology was used to fit a mathematical model to the data from 481 
each isolate. For Scedosporium datasets the structural mathematical model consisted of the 482 
following two inhomogeneous ordinary differential equations: 483 
 484 
dX1/dt= B(1)-(SCL/V)*X1    Equation 1 485 
dN/dt=Kgmax*(1-(N/POPMAX))*N   Equation 2a 486 
*(1-(X1/Vc)Hg/(X1/Vc)Hg+C50gHg))    Equation 2b 487 
 488 
with output equations 489 
Y(1)=X(1)/V      Equation 3 490 
Y(2)=X(2)      Equation 4 491 
 492 
Where: B(1) represents a bolus input of voriconazole into the central compartment, SCL is 493 
the clearance of drug from the circuit, Vc is the volume of the circuit, N is the antigen value, 494 
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Kgmax is the maximal rate of growth; POPMAX is the theoretical maximal antigen 495 
concentration within the circuit; Hg is the slope function for the suppression of growth; and, 496 
C50g is the concentration of drug in the circuit where there is half-maximal suppression of 497 
growth. 498 
Equation 1 describes the rate of change of the mass of voriconazole in the circuit.  Equation 2 499 
describes the rate of change of antigen in the circuit and contains terms that describe fungal 500 
growth in the absence of drug (Equation 2a) and the drug induced suppression of growth 501 
(Equation 2b). 502 
 503 
Pharmacodynamic Target Associated with Maximal Antifungal Activity 504 
 The mathematical model fitted to each strain was used to estimate the voriconazole 505 
area under the concentration-time curve and the area under the antigen-time curve.  Each 506 
circuit contributed one summary estimate of the effect of voriconazole. 507 
 The relationship between drug exposure and the effect on the biomarker was 508 
modelled using an inhibitory sigmoid Emax function that took the form: 509 
𝐸𝑓𝑓𝑒𝑐𝑡 = 𝐸𝑐𝑜𝑛 −
𝐸𝑚𝑎𝑥 ∗ 𝐷𝑟𝑢𝑔 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒𝐻
𝐸𝐶50
𝐻 + 𝐷𝑟𝑢𝑔 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒𝐻
 510 
Where: Econ is the antigen in controls, Emax is the maximum antifungal effect induced by 511 
voriconazole, Drug exposure is the AUC or AUC:MIC of voriconazole, H is the slope (Hill) 512 
function and EC50 is the voriconazole drug exposure where the effect is half maximal.  The 513 
model was fitted to the data using the pharmacokinetic program ADAPT5.  514 
 515 
Monte Carlo Simulation and Bridging Studies 516 
Monte Carlo simulations were performed in ADAPT 5 (22) using a previously 517 
published population pharmacokinetic model for voriconazole (23).  This model was fitted to 518 
data from healthy volunteers and patients receiving voriconazole therapy for proven or 519 
probable invasive aspergillosis.  The mean parameter values and their associated variances 520 
were used and embedded in subroutine PRIOR of ADAPT 5.  A log normal distribution was 521 
used and the ability of the simulation to reproduce the original parameter estimates and 522 
their dispersions was assessed.  A standard licenced regimen was used for the simulation (i.e. 523 
6 mg/kg i.v. q12h for two dosages followed by 4 mg/kg q12h i.v.).  Voriconazole was infused 524 
over 1 hour.  The AUC0-24 at the end of 5 days of therapy was calculated using integration.  525 
Each simulated patient’s AUC was divided by the MIC to calculate AUC:MIC for each MIC 526 
value.  The proportion of simulated patients achieving (or exceeding) the pharmacodynamic 527 
target at each MIC was determined.  The MICs used for these calculations were determined 528 
using CLSI methodology and provided by Professor Jacque Meis. 529 
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Table 1.  Challenge Strains of Scedosporium apiospermum 604 
 Antifungal Agenta 
Strainb AMB ITRA VORI POSA ISA ANI MICA 
8353 16 >16 0.5 1 4 8 0.5 
CNM-
CM6322 
8 >16 1 1 4 4 0.5 
CNM-
CM6386 
>16  >16 1 2 8 8 8 
 605 
aStrains of Scedosporium apiospermum used in this study and their minimum inhibitory 606 
concentrations (mg/L) determined using Clinical Laboratory Sciences Institute (CLSI) 607 
methodology. bAntifungal agents are as follows: AMB (amphotericin B), ITRA (itraconazole), 608 
VORI (voriconazole), POSA (posaconazole), ISA (isavuconazole), ANI (anidulafungin) and MICA 609 
(micafungin). 610 
  611 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 o
n
 February 14, 2018 by UNIVERSITY O
F EXETER
http://aac.asm
.org/
D
ow
nloaded from
 
 20 
 627 
Table 2. Parameters from the pharmacokinetic-pharmacodynamic model fitted to the 628 
experimental data from each strain. 629 
 630 
Parametera Strain 1 (8353) Strain 2 (6322) Strain 3 (6386) 
SCL (L/h) 0.021 0.019 0.030 
V (L) 0.646 0.850 1.036 
Kgmax (OD450/h) 0.036 0.013 0.021 
POPMAX (OD450) 1.808 2.068 2.999 
C50 (mg/L) 0.469 0.455 0.902 
Hg 5.582 9.932 2.155 
Initial Condition 
(OD450) 0.046 0.121 0.091 
 631 
aThe median parameter values are shown and are as follows: SCL (L/h) is the clearance of 632 
voriconazole from the circuit; V (L) is the volume of the central compartment; Kgmax is the 633 
maximum rate of fungal growth as estimated by the increase in fungal antigen liberated into 634 
the circuit; POPMAX is the maximum theoretical fungal density; C50 is the concentration of 635 
voriconazole where there is a 50% reduction in the rate of growth; Hg is the slope function 636 
and the Initial Condition is the estimated fungal density at time of treatment initiation (which 637 
is 12 hours postinoculation). 638 
 639 
 640 
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 641 
 642 
Figure 1. The time-course of antigen release in the in vitro static model.  Data are the mean  643 
standard deviation of three inserts.  Data were generated with strain 8353. 644 
 645 
  646 
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 647 
 648 
 649 
Figure 2.  The concentration-response relationships for the three challenge strains of 650 
Scedosporium apiospermum.  Data are mean  standard deviation.  The broken and solid 651 
lines are the fit of an inhibitory sigmoid Emax model to the data from the alveolar and 652 
endothelial compartments, respectively.  Panel A, strain 8353; Panel B,6386; Panel C 6322. 653 
 654 
 655 
 656 
  657 
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 658 
 659 
Figure 3.  Pharmacodynamics of voriconazole against Scedosporium apiospermum isolates 660 
from dynamic models of invasive pulmonary scedosporiosis.  Time zero is the time of 661 
treatment initiation and is 12 hours post inoculation.  Each line represents data from a single 662 
strain.  Voriconazole was administered at time = zero and every 12 hours thereafter.  Drug was 663 
administered as a bolus.  Pharmacodynamic samples were obtained from the endothelial 664 
compartment of the model.  The challenge strains are as follows: 6386 (red squares), 6322 665 
(green triangles) and 8353 (blue circles).  Panel A, Vehicle-treated control; Panel B, average 666 
AUC = 7.84 mg.h/L inducing negligible effect; Panel C, average AUC = 15.62 mg.h/L inducing 667 
submaximal antifungal activity, Panel D, average AUC = 80.68 mg.h/L inducing near maximal 668 
antifungal activity. 669 
 670 
 671 
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 673 
 674 
 675 
Figure 4. Observed-predicted values from the mathematical models fitted to the 676 
pharmacokinetic and pharmacodynamic data from each strain.  The broken line is the line of 677 
identity (observed = predicted).  678 
 679 
  680 
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 681 
 682 
 683 
Figure 5.  Panel A, The relationship between voriconazole AUC72-96 and the antifungal effect 684 
quantified in terms of the area under the antigen-time curve.  The inhibitory sigmoid Emax 685 
model is given by Area Under Antigen-Time Curve=25.71-686 
(16.69*(AUC)4.15/(13.424.15+(AUC)4.15)); r2 0.86; Panel B, The relationship between 687 
voriconazole AUC72-96:MIC and the antifungal effect quantified in terms of the area under the 688 
antigen-time curve.  The inhibitory sigmoid Emax model is given by Area Under Antigen-Time 689 
Curve=25.34-(17.14*(AUC:MIC)2.09/(22.8842.09+(AUC:MIC)2.09)); r2 0.82.  690 
 691 
  692 
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 693 
 694 
Figure 6. The probability of target attainment for a regimen of i.v. voriconazole 6 mg/kg q12h 695 
for two dosages followed by 4 mg/kg q12h thereafter.  Drug was infused over 1 hour.  A 696 
weight of 75 kg was used for the simulations and the AUC0-24 was determined at the end of 697 
day 5.  The fraction of 5,000 simulated patients that achieved an AUC:MIC of >100 for each 698 
MIC value is shown by the solid squares.  The MIC distribution of S. apiospermum from 77 699 
strains is shown by the open triangles.  The overall expectation of target attainment for the 700 
population is 34%. 701 
 702 
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